Evidence map›Paper›PMID 36230482›Full record

ArticleCancers2022

Engraftment of Allotransplanted Tumor Cells in Adult

Dieter Tulkens, Dionysia Dimitrakopoulou, Marthe Boelens, Tom Van Nieuwenhuysen, Suzan Demuynck, Wendy Toussaint, David Creytens, Pieter Van Vlierberghe, Kris Vleminckx

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Dieter TulkensDepartment of Biomedical Molecular Biology, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0003-1688-5619
Dionysia DimitrakopoulouDepartment of Biomedical Molecular Biology, Ghent University, 9000 Ghent, Belgium.
Marthe BoelensDepartment of Biomedical Molecular Biology, Ghent University, 9000 Ghent, Belgium.
Tom Van NieuwenhuysenDepartment of Biomedical Molecular Biology, Ghent University, 9000 Ghent, Belgium.
Suzan DemuynckDepartment of Biomedical Molecular Biology, Ghent University, 9000 Ghent, Belgium.
Wendy ToussaintDepartment of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.
David CreytensCancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.ORCID 0000-0002-6064-1673
Pieter Van VlierbergheCancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.ORCID 0000-0001-9063-7205
Kris VleminckxDepartment of Biomedical Molecular Biology, Ghent University, 9000 Ghent, Belgium.
Ghent University · BEGhent University Hospital · BE

Funding

Desmoid Foundation Canada DFC-VleminckxDesmoid Tumor Research Foundation DTRF-VleminckxGhent University BOF15/GOA/011Ghent University BOF20/GOA/023Research Foundation - Flanders G029413NResearch Foundation - Flanders G0A1515N
6 · The paper itself

Abstract

Modeling human genetic diseases and cancer in lab animals has been greatly aided by the emergence of genetic engineering tools such as TALENs and CRISPR/Cas9. We have previously demonstrated the ease with which genetically engineered

Indexed as

genetic cancer modelimmunocompromisedrag2 knockouttumor transplantationsXenopus

Identifiers

PMID36230482
PMCPMC9559464
OpenAlexW4296467046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.